Skip to main content

Table 1 Clinical characteristics of the study subjects

From: The combination of nonthyroidal illness syndrome and renal dysfunction further increases mortality risk in patients with acute myocardial infarction: a prospective cohort study

Variables

Normal

(n = 692)

NTIS

(n = 139)

Renal dysfunction (n = 304)

Combined (n = 160)

P value

P value*

Age (years)

65 ± 13

70 ± 12

75 ± 9

77 ± 10

< 0.001

< 0.001

Male(n,%)

536 (77.5%)

78 (56.1%)

147 (48.4%)

97 (60.6%)

< 0.001

0.001

Hypertension(n,%)

403 (58.2%)

83 (59.7%)

227 (74.7%)

107 (66.9%)

< 0.001

0.112

Diabetes mellitus (n,%)

181 (26.2%)

46 (33.1%)

111 (36.5%)

61 (38.1%)

0.001

0.001

Smoking(n,%)

452 (65.5%)

82 (59.0%)

150 (49.3%)

81 (50.6%)

< 0.001

0.083

Alcohol(n,%)

50 (7.3%)

5 (3.6%)

7 (2.3%)

6 (3.8%)

0.006

0.597

SBP (mmHg)

128 ± 22

123 ± 23

132 ± 24

127 ± 26

0.003

< 0.001

DBP (mmHg)

75 ± 13

70 ± 13

73 ± 13

72 ± 14

0.001

< 0.001

BMI (kg/m2)

24.24 ± 2.04

23.36 ± 2.53

23.55 ± 2.53

23.46 ± 2.66

< 0.001

0.03

WBC (×109/l)

8.64 ± 3.69

9.71 ± 4.90

8.30 ± 3.98

9.98 ± 4.91

< 0.001

< 0.001

Hb (g/l)

139 ± 15

129 ± 16

124 ± 17

116 ± 20

< 0.001

< 0.001

Alb (g/l)

41 ± 6

38 ± 6

40 ± 5

37 ± 6

< 0.001

0.001

CRP (mg/l)

3.4 (1.6–6.5)

10.0 (4.8–21.3)

5.1 (3.5–8.0)

18.2 (8.8–33.0)

< 0.001

< 0.001

TG (mmol/l)

1.54 ± 0.91

1.37 ± 1.07

1.40 ± 0.80

1.30 ± 0.91

< 0.001

0.005

TC (mmol/l)

4.60 ± 1.15

4.64 ± 1.15

4.34 ± 1.14

4.24 ± 1.17

0.007

< 0.001

HDL-C(mmol/l)

1.05 (0.90–1.22)

1.05 (0.93–1.21)

1.06 (0.85–1.23)

1.03 (0.87–1.20)

0.361

0.245

LDL-C(mmol/l)

2.92 (2.34–3.55)

2.80 (2.23–3.55)

2.67 (2.09–3.44)

2.56 (2.02–3.25)

< 0.001

0.547

FPG (mmol/l)

6.98 ± 3.30

7.95 ± 3.65

7.10 ± 3.31

7.60 ± 3.07

0.003

0.007

FT3(pmol/l)

4.05 ± 0.55

2.60 ± 0.47

3.88 ± 0.53

2.52 ± 0.46

< 0.001

< 0.001

FT4(pmol/l)

16.15 ± 2.23

15.26 ± 2.06

16.52 ± 2.30

15.17 ± 2.53

< 0.001

< 0.001

TSH(mU/l)

1.30 (0.75–2.12)

1.26 (0.57–1.94)

1.47 (0.98–2.29)

1.25 (0.59–1.84)

< 0.001

0.004

sCr (μmol/l)

76 (65–88)

74 (60–89)

118 (102–142)

135 (109–178)

< 0.001

< 0.001

eGFR(ml/min/1.73m2)

89.69 ± 29.58

86.77 ± 28.15

44.03 ± 12.90

39.84 ± 14.50

< 0.001

< 0.001

Antiplatelet agents(n,%)

446 (64.6%)

93 (66.9%)

180 (59.2%)

96 (60.0%)

0.241

0.491

β-blockers(n,%)

379 (55.0%)

77 (55.4%)

217 (71.4%)

110 (68.8%)

< 0.001

0.005

LLDs (n,%)

462 (67.0%)

95 (68.3%)

158 (52.1%)

92 (57.5%)

< 0.001

0.040

ACEIs/ARBs(n,%)

363 (52.6%)

89 (64.0%)

140 (46.2%)

70 (43.8%)

0.001

0.133

CCBs (n,%)

81 (11.7%)

12 (8.6%)

39 (12.8%)

19 (11.9%)

0.649

0.922

Diuretics(n,%)

492 (71.2%)

116 (83.5%)

210 (69.1%)

114 (71.3%)

0.014

0.873

Revascularization during the present hospitalization(n,%)

539 (77.9%)

98 (70.5%)

163 (53.6%)

68 (42.5%)

< 0.001

< 0.001

Prior PCI or CABG (n,%)

24 (3.5%)

4 (2.9%)

6 (2.0%)

6 (3.8%)

0.604

0.622

Infarct type (NSTEMI n,%)

42 (6.1%)

11 (7.9%)

17 (5.6%)

12 (7.5%)

0.725

0.627

  1. Values are expressed as mean ± SD,median with interquartile range or percentages
  2. The p values were not adjusted for age and sex for the trend
  3. The p values* were adjusted for age and sex for the trend
  4. Revascularization included percutaneous coronary intervention (PCI) and coronary artery bypass graft (CABG)